All WA babies under eight months old, as well as those aged eight to 19 months at increased risk of severe RSV infection, will be eligible for monoclonal antibodies.
In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).
The 2023 influenza season is expected to start early and be more severe than the last few years. It’s important for front line immunisers to be updated with the latest information, public health advice and practical strategies for this year’s season. Influenza causes a large burden of disease in Australia with sick days, hospitalisation and death. Vaccination is readily available and updated yearly to include the most recent strains. It is widely recommended across the community, but especially for the most vulnerable including the very young, old, Indigenous Australians, and people with underlying comorbidities.
In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains the recombinant protein nanoparticle COVID-19 vaccine with a proprietary adjuvant, including the mechanism of action, efficacy, and tolerability; and provides an update on boosters, indications, and access
(8 mins).
In this Product Explainer, Public Health Physician A/Prof John Litt AM explains the currently funded adjuvanted quadrivalent influenza vaccine for people 65 years and over and how it fits in the 2023 influenza season (6 mins).This product explainer is supported by Seqirus
In this Product Explainer, Paediatrician Dr Daryl Cheng explains the role of the MenACWY-TT conjugate vaccine for invasive meningococcal disease, the importance of adolescent vaccination and opportunistic immunisation, and the healthcare professional’s role in improving uptake rates in this age group
(7 mins).
In this Product Explainer, Public Health Physician Prof Paul Van Buynder explains the role of the Bivalent Original/Omicron BA.4-5 pre-filled syringe COVID-19 vaccine and provides an update on the situation in aged care, and how boosters can assist in protecting the community against symptomatic infection and severe disease (5 mins).
Rosacea – Smarter diagnosis & state-of-the-art care
Tuesday 14th April, 7pm - 9pm AEST
Speaker
Dr Belinda Welsh
Dermatologist; Senior Vice President, Australasian Society of Cosmetic Dermatologists
Join Dr Belinda Welsh, who will also present a practical framework for the effective management of rosacea, a condition that can be controlled by not cured.